Semaglutide vs. tirzepatide: how they differ
Semaglutide and tirzepatide are prescription medications used in clinician-supervised weight-management programs. Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on both GIP and GLP-1 receptors. A licensed provider can help determine whether either option is appropriate based on your health history, current medications, and treatment goals.
What they have in common
Both medications can reduce appetite and are used alongside nutrition and lifestyle changes. Treatment generally begins with a dose selected by the prescriber and may be adjusted over time. Neither medication is appropriate for everyone, and individual results vary.
How the choice is made
The right option depends on more than expected weight loss. Your provider considers contraindications, prior treatment, tolerability, drug interactions, and the available pharmacy formulations. Tell your provider about your full medical history, including any personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Current Revelry programs
Revelry offers online evaluation for four-week compounded semaglutide and tirzepatide programs. Current program pricing is displayed on the product page and at Revelry's secure checkout. The licensed provider determines the appropriate pharmacy and treatment package during clinical review. Compounded medications are not FDA-approved finished drug products, and a prescription is issued only when clinically appropriate.